The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

The Gilead Road Bridge over I-77 in Huntersville, NC, will be closed from May 2 at 9 p.m. to May 5 at 6 a.m. for interchange ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

With cross-country expanding from three to four postseason divisions, the OHSAA on April 24 announced divisional alignments ...

(GILD) on Thursday reported first-quarter earnings of $1.32 billion. The Foster City, California-based company said it had net income of $1.04 per share. Earnings, adjusted for costs related to ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...

"The Handmaid's Tale" may be coming to an end, but the world of Gilead is not with a sequel, "The Testaments," in production ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...